A Phase 1/1b Open-label Multicenter Study to Investigate the Safety Tolerability Pharmacokinetics and Antitumor Activity of KIN-2787 in Participants with BRAF and/or NRAS Mutation-positive Solid Tumors.

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Solid Tumors
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    -Histologically or cytologically confirmed diagnosis of metastatic or advanced-stage malignancy, as follows: • Part A – Any advanced or metastatic solid tumor • Part B Cohort 1 – Unresectable and locally advanced (AJCC Stage III) or metastatic (AJCC Stage IV) NSCLC • Part B Cohort 2 – Unresectable and locally advanced (AJCC Stage III) or metastatic (AJCC Stage IV) melanoma • Part B Cohort 3 – Any unresectable and locally advanced (AJCC Stage III, or comparable Stage with other staging systems) or metastatic (AJCC Stage IV) solid tumor other than NSCLC or melanoma. Participants must have received prior locally approved standard of care appropriate for their tumor type and stage of disease.

You may not be eligible for this study if the following are true:

  • Participants who have had brain metastases resected or have received radiation therapy ending at least 4 weeks prior to Cycle 1 Day 1 are eligible if they meet all of the following criteria: • Residual neurological symptoms grade = 2 • On stable doses of dexamethasone (i.e., no increase in dose for preceding 14 days), if applicable • Follow-up magnetic resonance imaging (MRI) shows no new lesions appearing. -In Part A, for participants with other solid tumors (other than NSCLC, melanoma, CRC, and anaplastic thyroid cancer) driven by BRAF Class I mutations, prior treatment with any approved or in-development small molecule BRAF-, MEK-, or MAPK-directed inhibitor therapy. This criterion will not be implemented until a decision to do so is made and communicated by the DRC. -In Part B, previous treatment with any approved or in-development small molecule BRAF-,MEK-, or MAPK-directed inhibitor therapy.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.